Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Taiwan - Delayed Quote TWD

SciVision Biotech Inc. (1786.TW)

Compare
114.50
0.00
(0.00%)
At close: April 2 at 1:30:08 PM GMT+8
Loading Chart for 1786.TW
  • Previous Close 114.50
  • Open 115.00
  • Bid 114.00 x --
  • Ask 115.00 x --
  • Day's Range 112.50 - 115.50
  • 52 Week Range 88.60 - 144.00
  • Volume 454,219
  • Avg. Volume 1,150,516
  • Market Cap (intraday) 8.227B
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) 34.70
  • EPS (TTM) 3.30
  • Earnings Date --
  • Forward Dividend & Yield 3.25 (2.84%)
  • Ex-Dividend Date Apr 25, 2025
  • 1y Target Est --

SciVision Biotech Inc. manufactures and sells hyaluronic acid medical products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in the wholesale of medical equipment; and provides management consulting services. SciVision Biotech Inc. was founded in 1990 and is based in Kaohsiung, Taiwan.

www.scivision.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1786.TW

View More

Performance Overview: 1786.TW

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

1786.TW
10.10%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.54%

1-Year Return

1786.TW
4.08%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
4.06%

3-Year Return

1786.TW
192.37%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
20.84%

5-Year Return

1786.TW
216.63%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
120.40%

Compare To: 1786.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1786.TW

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    8.23B

  • Enterprise Value

    7.58B

  • Trailing P/E

    34.70

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.65

  • Price/Book (mrq)

    4.34

  • Enterprise Value/Revenue

    8.58

  • Enterprise Value/EBITDA

    20.91

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    27.43%

  • Return on Assets (ttm)

    6.87%

  • Return on Equity (ttm)

    13.75%

  • Revenue (ttm)

    883.31M

  • Net Income Avi to Common (ttm)

    242.25M

  • Diluted EPS (ttm)

    3.30

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    805.92M

  • Total Debt/Equity (mrq)

    11.82%

  • Levered Free Cash Flow (ttm)

    134.06M

Research Analysis: 1786.TW

View More

Company Insights: 1786.TW

Research Reports: 1786.TW

View More

People Also Watch